Business
Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)
Nataliya Agafonova Nataliya Agafonova, M.D., Chief Medical Officer, Longeveron Accepted IND application allows for development program to move directly to a Phase 2 pivotal registration clinical trialPhase 2 clinical trial initiation anticipated in first half of 2026Pediatric cardiomyopathies affect at least 100,000 children worldwideEffective treatment options are limited, with nearly 40% of children with DCM requiring a heart transplant or dying within two years of diagnosis MIAMI, July 08, 20
About this update from Longeveron Inc.
[{"type":"image","alt":"Longeveron","displaySize":"","headline":null,"caption":"Longeveron","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/7020f3e4e4ad01a05af1150b74d0406a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.X2J.blw.0f9XkdGnRbwAQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/7020f3e4e4ad01a05af1150b74d0406a","width":300,"height":56}},"lazy":false},{"type":"text","content":"Nataliya Agafonova","length":18,"tagName":"p"},{"type":"image","alt":"Nataliya Agafonova, M.D., Chief Medical Officer, Longeveron","displaySize":"","headline":null,"caption":"Nataliya Agafonova, M.D., Chief Medical Officer, Longeveron","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":109,"height":119,"url":"https://media.zenfs.com/en/globenewswire.com/025b5ef53f21da23bcd9028e2d842f1a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/D0k9wSAfkbUqGepOFlp68A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIyOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/025b5ef53f21da23bcd9028e2d842f1a","width":109,"height":119}}},{"type":"list","items":[{"val":[{"type":"text","content":"Accepted IND application allows for development program to move directly to a Phase 2 pivotal registration clinical trial","length":121,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase 2 clinical trial initiation anticipated in first half of 2026","length":67,"tagName":"p"}]},{"val":[{"type":"text","content":"Pediatric cardiomyopathies affect at least 100,000 children worldwide","length":69,"tagName":"p"}]},{"val":[{"type":"text","content":"Effective treatment options are limited, with nearly 40% of children with DCM requiring a heart transplant or dying within two years of diagnosis","length":145,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":402,"olType":false},{"type":"text","content":"MIAMI, July 08, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its stem cell therapy laromestrocel as a potentia...